{"id":701743,"date":"2022-10-27T08:05:29","date_gmt":"2022-10-27T12:05:29","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-to-report-third-quarter-2022-financial-results\/"},"modified":"2022-10-27T08:05:29","modified_gmt":"2022-10-27T12:05:29","slug":"kura-oncology-to-report-third-quarter-2022-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-to-report-third-quarter-2022-financial-results\/","title":{"rendered":"Kura Oncology to Report Third Quarter 2022 Financial Results\u00a0\u00a0"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SAN DIEGO, Oct.  27, 2022  (GLOBE NEWSWIRE) &#8212; Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report third quarter 2022 financial results before U.S. financial markets open on Thursday, November 3, 2022. Kura\u2019s management will host a webcast and conference call at 8:00 a.m. ET \/ 5:00 a.m. PT that day to discuss the financial results and provide a corporate update.\u00a0<\/p>\n<p>To participate in the teleconference, domestic callers should dial 1-888-394-8218 and international callers should dial 1-323-994-2093 and reference conference ID: 2251807.\u00a0A live webcast presentation can also be accessed using this weblink: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OF1mF4wof9GoM9O9vj6ke60b0CLAJsCtI11HHydDegKGtH_Rfb_39QoT25ETbmwTqHk9vOXDrFUMZ31NVUgIuTfgrT1wWuRRaWmJvju482QzsIyXv3pXIrxzaNC014pnUrtyMNO_07s1U2CLEUfNFQSCdlgUkKmZT9ZTC-VMwCqAVS8_tY1I1Lk1rF5UFLWAVFqh24RO7dwf7aeweAwr3X-VAz60n8N_PZ76hhLtq6w=\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/viavid.webcasts.com\/starthere.jsp?ei=1576867&amp;tp_key=fe0ec98bea<\/a>. A replay of the webcast will be available online from the investor relations section of the company website at www.kuraoncology.com.<\/p>\n<p>\n        <strong>About Kura Oncology<\/strong>\u00a0<\/p>\n<p>Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company\u2019s pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib (KO-539), a potent and selective menin inhibitor, is currently in a Phase 1b clinical trial (KOMET-001) for patients with relapsed\/refractory acute myeloid leukemia, including patients with NPM1 mutations or KMT2A rearrangements. Tipifarnib, a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI), has received Breakthrough Therapy Designation for the treatment of patients with HRAS mutant head and neck squamous cell carcinoma (HNSCC) and is currently in a registration-directed trial (AIM-HN) in patients with this devastating disease. In addition, Kura is conducting a Phase 1\/2 trial (KURRENT-HN) of tipifarnib in combination with the PI3K\u03b1 inhibitor alpelisib to address larger genetic subsets of HNSCC patients, including those whose tumors are dependent on HRAS and\/or PI3K\u03b1 pathways. The Company is also preparing to initiate a Phase 1 trial (KURRENT-LUNG) of tipifarnib in combination with osimertinib in treatment-na\u00efve locally advanced\/metastatic EGFR mutated non-small cell lung cancer. Kura intends to perform initial clinical evaluation with tipifarnib while in parallel advancing KO-2806, the Company\u2019s next-generation FTI, through IND-enabling studies. For additional information, please visit Kura\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RPSyrPK9urMlutsGzHpUByJxvS2tP2awJj66ySzsAiDQN8FB_MmzPSdvWj2MOerZ2tMZURnkH_MMglIbS4NbeMjkFA8zNQWOGK0INsLoAiU=\" rel=\"nofollow noopener\" target=\"_blank\">www.kuraoncology.com<\/a>.<\/p>\n<p>\n        <strong>Contacts<\/strong>\n      <\/p>\n<p>Company:<br \/>Pete De Spain<br \/>Senior Vice President, Investor Relations &amp;<br \/>Corporate Communications<br \/>(858) 500-8803<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=r3tYuQJixTSssOl_Bd9w21SC6b5PhGem4YtSmWLbKlzGrGGs1_uCR_BAcvKGJYJGKrLzvFnIU5Nn_t1QzfsTj_ja9OVlTdcjLuVrpdO1jNI=\" rel=\"nofollow noopener\" target=\"_blank\"><u>pete@kuraoncology.com<\/u><\/a><\/p>\n<p>Investors:<br \/>Robert H. Uhl<br \/>Managing Director<br \/>ICR Westwicke<br \/>(858) 356-5932<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SB7uYTZ2nC5fzs48tIYm8ViTHwwdJ_2K3PDdYVvE1o2kvioH3KCBE2KGoWE84mIT6qRO3IKo9_KeqzO3ltbHzscWuFZZCcw6bz5hxBM6gvM=\" rel=\"nofollow noopener\" target=\"_blank\"><u>robert.uhl@westwicke.com<\/u><\/a><\/p>\n<p>Media:<br \/>Jason Spark<br \/>Managing Director<br \/>Canale Communications<br \/>(619) 849-6005<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=a2GYirBSm7uFnHPuVMXrVKEuAAM26o-yxOu-ctLFaHp_bKvxLywTE6k18Ux2s1ZX6C5POJCra82Jh_RfE0-Hnt22JxhBffj4AzQGPsrAjBg=\" rel=\"nofollow noopener\" target=\"_blank\"><u>jason@canalecomm.com<\/u><\/a><\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY4MzI3NiM1MjI3MDg1IzIwMTcxOTU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ZDJmNjljOWUtNWE4MC00ZTZmLWJmOGItMTM0M2QyNjhmNmZmLTEwMjg3Njg=\/tiny\/Kura-Oncology-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) &#8212; Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report third quarter 2022 financial results before U.S. financial markets open on Thursday, November 3, 2022. Kura\u2019s management will host a webcast and conference call at 8:00 a.m. ET \/ 5:00 a.m. PT that day to discuss the financial results and provide a corporate update.\u00a0 To participate in the teleconference, domestic callers should dial 1-888-394-8218 and international callers should dial 1-323-994-2093 and reference conference ID: 2251807.\u00a0A live webcast presentation can also be accessed using this weblink: https:\/\/viavid.webcasts.com\/starthere.jsp?ei=1576867&amp;tp_key=fe0ec98bea. A replay of the webcast will be available &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-to-report-third-quarter-2022-financial-results\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Kura Oncology to Report Third Quarter 2022 Financial Results\u00a0\u00a0&#8220;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-701743","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Kura Oncology to Report Third Quarter 2022 Financial Results\u00a0\u00a0 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-to-report-third-quarter-2022-financial-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kura Oncology to Report Third Quarter 2022 Financial Results\u00a0\u00a0 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) &#8212; Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report third quarter 2022 financial results before U.S. financial markets open on Thursday, November 3, 2022. Kura\u2019s management will host a webcast and conference call at 8:00 a.m. ET \/ 5:00 a.m. PT that day to discuss the financial results and provide a corporate update.\u00a0 To participate in the teleconference, domestic callers should dial 1-888-394-8218 and international callers should dial 1-323-994-2093 and reference conference ID: 2251807.\u00a0A live webcast presentation can also be accessed using this weblink: https:\/\/viavid.webcasts.com\/starthere.jsp?ei=1576867&amp;tp_key=fe0ec98bea. A replay of the webcast will be available &hellip; Continue reading &quot;Kura Oncology to Report Third Quarter 2022 Financial Results\u00a0\u00a0&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-to-report-third-quarter-2022-financial-results\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-27T12:05:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY4MzI3NiM1MjI3MDg1IzIwMTcxOTU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kura-oncology-to-report-third-quarter-2022-financial-results\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kura-oncology-to-report-third-quarter-2022-financial-results\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Kura Oncology to Report Third Quarter 2022 Financial Results\u00a0\u00a0\",\"datePublished\":\"2022-10-27T12:05:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kura-oncology-to-report-third-quarter-2022-financial-results\\\/\"},\"wordCount\":410,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kura-oncology-to-report-third-quarter-2022-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY4MzI3NiM1MjI3MDg1IzIwMTcxOTU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kura-oncology-to-report-third-quarter-2022-financial-results\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kura-oncology-to-report-third-quarter-2022-financial-results\\\/\",\"name\":\"Kura Oncology to Report Third Quarter 2022 Financial Results\u00a0\u00a0 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kura-oncology-to-report-third-quarter-2022-financial-results\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kura-oncology-to-report-third-quarter-2022-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY4MzI3NiM1MjI3MDg1IzIwMTcxOTU=\",\"datePublished\":\"2022-10-27T12:05:29+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kura-oncology-to-report-third-quarter-2022-financial-results\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kura-oncology-to-report-third-quarter-2022-financial-results\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kura-oncology-to-report-third-quarter-2022-financial-results\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY4MzI3NiM1MjI3MDg1IzIwMTcxOTU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY4MzI3NiM1MjI3MDg1IzIwMTcxOTU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kura-oncology-to-report-third-quarter-2022-financial-results\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kura Oncology to Report Third Quarter 2022 Financial Results\u00a0\u00a0\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kura Oncology to Report Third Quarter 2022 Financial Results\u00a0\u00a0 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-to-report-third-quarter-2022-financial-results\/","og_locale":"en_US","og_type":"article","og_title":"Kura Oncology to Report Third Quarter 2022 Financial Results\u00a0\u00a0 - Market Newsdesk","og_description":"SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) &#8212; Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report third quarter 2022 financial results before U.S. financial markets open on Thursday, November 3, 2022. Kura\u2019s management will host a webcast and conference call at 8:00 a.m. ET \/ 5:00 a.m. PT that day to discuss the financial results and provide a corporate update.\u00a0 To participate in the teleconference, domestic callers should dial 1-888-394-8218 and international callers should dial 1-323-994-2093 and reference conference ID: 2251807.\u00a0A live webcast presentation can also be accessed using this weblink: https:\/\/viavid.webcasts.com\/starthere.jsp?ei=1576867&amp;tp_key=fe0ec98bea. A replay of the webcast will be available &hellip; Continue reading \"Kura Oncology to Report Third Quarter 2022 Financial Results\u00a0\u00a0\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-to-report-third-quarter-2022-financial-results\/","og_site_name":"Market Newsdesk","article_published_time":"2022-10-27T12:05:29+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY4MzI3NiM1MjI3MDg1IzIwMTcxOTU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-to-report-third-quarter-2022-financial-results\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-to-report-third-quarter-2022-financial-results\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Kura Oncology to Report Third Quarter 2022 Financial Results\u00a0\u00a0","datePublished":"2022-10-27T12:05:29+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-to-report-third-quarter-2022-financial-results\/"},"wordCount":410,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-to-report-third-quarter-2022-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY4MzI3NiM1MjI3MDg1IzIwMTcxOTU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-to-report-third-quarter-2022-financial-results\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-to-report-third-quarter-2022-financial-results\/","name":"Kura Oncology to Report Third Quarter 2022 Financial Results\u00a0\u00a0 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-to-report-third-quarter-2022-financial-results\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-to-report-third-quarter-2022-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY4MzI3NiM1MjI3MDg1IzIwMTcxOTU=","datePublished":"2022-10-27T12:05:29+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-to-report-third-quarter-2022-financial-results\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-to-report-third-quarter-2022-financial-results\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-to-report-third-quarter-2022-financial-results\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY4MzI3NiM1MjI3MDg1IzIwMTcxOTU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY4MzI3NiM1MjI3MDg1IzIwMTcxOTU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kura-oncology-to-report-third-quarter-2022-financial-results\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Kura Oncology to Report Third Quarter 2022 Financial Results\u00a0\u00a0"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/701743","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=701743"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/701743\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=701743"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=701743"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=701743"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}